XML 48 R45.htm IDEA: XBRL DOCUMENT v2.4.1.9
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Accounting Policies) (Details) (USD $)
0 Months Ended 12 Months Ended
Jan. 27, 2014
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Jan. 27, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Common stock, par value (in usd per share) $ 0.01us-gaap_CommonStockParOrStatedValuePerShare [1] $ 0.01us-gaap_CommonStockParOrStatedValuePerShare [1] $ 0.01us-gaap_CommonStockParOrStatedValuePerShare [1]   $ 0.01us-gaap_CommonStockParOrStatedValuePerShare [1]
Prior period reclassification     $ 1,700,000us-gaap_PriorPeriodReclassificationAdjustment $ 1,900,000us-gaap_PriorPeriodReclassificationAdjustment  
Common stock reverse stock split, conversion ratio 0.0833us-gaap_StockholdersEquityNoteStockSplitConversionRatio1        
Impairment of goodwill   0us-gaap_GoodwillImpairmentLoss      
Decrease in amortization expense   400,000tbio_FiniteLivedIntangibleAssetsChangeinAmortizationExpense      
Impairment of intangibles   0us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill 0us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill 0us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill  
Equity awards, contractual term   10 years      
Deferred revenue   1,035,000us-gaap_DeferredRevenueCurrent 1,088,000us-gaap_DeferredRevenueCurrent    
Foreign currency translation adjustment   (50,000)us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax (45,000)us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax 99,000us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax  
Foreign currency translation income (loss) (less than)   (100,000)us-gaap_ForeignCurrencyTransactionGainLossRealized 100,000us-gaap_ForeignCurrencyTransactionGainLossRealized (100,000)us-gaap_ForeignCurrencyTransactionGainLossRealized  
Options, warrants and conversion rights, common stock callable and antidilutive (in shares)   6,613,572us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount 3,785,709us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount 2,471,670us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount  
Pharmacogenomic services          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Deferred revenue   300,000us-gaap_DeferredRevenueCurrent
/ us-gaap_StatementBusinessSegmentsAxis
= tbio_PharmacogenomicServicesMember
200,000us-gaap_DeferredRevenueCurrent
/ us-gaap_StatementBusinessSegmentsAxis
= tbio_PharmacogenomicServicesMember
   
Diagnostic tools          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Deferred revenue   $ 700,000us-gaap_DeferredRevenueCurrent
/ us-gaap_StatementBusinessSegmentsAxis
= tbio_DiagnosticToolsMember
$ 900,000us-gaap_DeferredRevenueCurrent
/ us-gaap_StatementBusinessSegmentsAxis
= tbio_DiagnosticToolsMember
   
Minimum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Equity awards, vesting period   1 year      
Maximum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Equity awards, vesting period   3 years      
Familion | Minimum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Estimated economic life   7 years      
Familion | Maximum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Estimated economic life   10 years      
[1] The common stock shares and additional paid-in capital for all periods presented reflect the one-for-twelve reverse stock split which took effect on January 27, 2014.